LLY
Eli Lilly and Company
LLY has the edge over NNOX overall, supported by stronger fundamentals and lower modeled downside.
NNOX
Nano-X Imaging Ltd.
NNOX's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NNOX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
NNOX's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NNOX PE Valuation
NNOX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NNOX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect NNOX's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over NNOX on earnings quality, reporting a profit while its opponent remains loss making.
NNOX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.70 | -$0.80 |
| Q1 2026 | -$1.14 | -$0.24 |
| Q4 2025 | -$1.15 | -$0.25 |
| Q3 2025 | -$0.88 | -$0.03 |
| Q2 2025 | -$0.90 | +$0.09 |
| Q1 2025 | -$0.90 | +$0.17 |
| Q4 2024 | -$0.90 | +$0.17 |
| Q3 2024 | -$0.85 | +$0.90 |
NNOX is still losing money, but less than at its worst: $1.70 per share over the past year, against $2.03 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over NNOX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NNOX on profitability, with a higher operating margin.
NNOX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $4.2M | +37% |
| Q1 2026 | $4.3M | +53% |
| Q4 2025 | $3.7M | +24% |
| Q3 2025 | $3.4M | +14% |
| Q2 2025 | $3M | +13% |
| Q1 2025 | $2.8M | +10% |
| Q4 2024 | $3M | +25% |
| Q3 2024 | $3M | +22% |
NNOX's revenue has grown year over year for 19 quarters in a row: $4M last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1335% | -858 points |
| Q1 2026 | -343% | +157 points |
| Q4 2025 | -481% | +18 points |
| Q3 2025 | -413% | +54 points |
| Q2 2025 | -477% | +61 points |
| Q1 2025 | -501% | +12 points |
| Q4 2024 | -499% | +54 points |
| Q3 2024 | -466% | +421 points |
NNOX's operating margin was −1335% last quarter, down 858 points from the same quarter a year ago, near the bottom of its range since 2021.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over NNOX on cash generation, producing positive trailing cash flow while its opponent burns cash.
NNOX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$12.6M | -$2.2M |
| Q1 2026 | -$15.7M | -$4.9M |
| Q4 2025 | -$12.5M | -$922.8K |
| Q3 2025 | -$12.5M | -$3.6M |
| Q2 2025 | -$10.4M | -$1M |
| Q1 2025 | -$10.9M | -$1.3M |
| Q4 2024 | -$11.6M | +$890.5K |
| Q3 2024 | -$8.9M | +$3.5M |
NNOX has burned cash in almost every quarter: −$53M over the past year, against −$42M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NNOX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NNOX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +312K shares |
| 1 year | +9.4% | +6M shares |
| 3 years | +26% | +14.6M shares |
| 5 years | +46% | +22.2M shares |
| Available history | +105% | +35.8M shares |
NNOX has 70M diluted shares, up 9.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
NNOX hasn't bought back shares in the past year.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NNOX Net Leverage
NNOX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NNOX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.9 | Oversold |
| Stochastic | 7.0 | Oversold |
NNOX's weekly RSI is 27 (oversold) and its Stochastic is 7 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NNOX PE vs Healthcare Sector
NNOX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NNOX on trend strength, trading above more of its moving averages.
NNOX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.44 | 27% below |
| 20 week MA | $0.75 | 57% below |
| 50 week MA | $1.73 | 82% below |
| 100 week MA | $3.50 | 91% below |
| 200 week MA | $6.06 | 95% below |
NNOX is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over NNOX on returns for 2026, with the stronger performance.
NNOX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $49.6 | $52.5 | +5.7% |
| 2021 | $52.5 | $17.9 | -66% |
| 2022 | $17.9 | $8.02 | -55% |
| 2023 | $8.02 | $6.37 | -21% |
| 2024 | $6.37 | $7.59 | +19% |
| 2025 | $7.59 | $2.86 | -62% |
| 2026 YTD | $2.86 | $0.32 | -89% |
NNOX has finished lower in four of the last six years. It's down 89% so far in 2026.